Recommended dilution: IHC: 1:100 - 1:200 Positive and negative controls should be simultaneously run with unknown specimens, as there are no conclusive characteristics to suggest instability of the antibody. The prediluted antibody does not require any mixing, dilution, reconstitution, or titration; the antibody is ready-to-use and optimized for staining. The concentrated antibody requires dilution in the optimized buffer, to the recommended working dilution range (as above).
My Review for Mouse Anti-Human BRCA1 monoclonal antibody, clone JID512
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
References
Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection
BRCA-associated hereditary breast and ovarian cancer syndrome (HBOC) is characterized by an increased risk of developing other malignancies including cholangiocarcinoma (CCA). Somatic BRCA mutations have been reported in CCA, but they have yet to be utilized in a proband case to identify HBOC in families. Two healthy daughters of a deceased female patient who had had metachronous breast cancer and CCA received genetic counseling to assess their cancer risk. SomaticBRCA1/2mutation analysis was performed by next-generation sequencing on the DNA extracted from a formalin-fixed, paraffin-embedded CCA biopsy specimen of their mother. A pathogenic variant was identified (c.6468_6469delTC in a BRCA2 gene mutation). Germline BRCA mutation analysis of the two daughters detected the same pathogenic variant in one of them. For the first time, a CCA somatic BRCA mutation has been used to identify a family with HBOC.
A low fouling electrochemical biosensor based on the zwitterionic polypeptide doped conducting polymer PEDOT for breast cancer marker BRCA1 detection
The application of polypeptides in bio-interfaces and biosensors is of great interest because polypeptides are biocompatible and easy to design. A novel polymer nanocomposite was prepared by the electropolymerization of the conducting polymer poly(3,4-ethylenedioxythiophene) (PEDOT) with a newly designed polypeptide. The nanocomposite polypeptide doped PEDOT (PEDOT/PEP), with a 3D microporous network structure, large surface area and excellent antifouling ability, was utilized for the attachment of BRCA1 complementary oligonucleotides to construct a DNA biosensor. The fabricated DNA biosensor showed favorable selectivity (with a detection limit of 0.0034 pM) and high sensitivity. The biosensor was also capable of detecting the target DNA (BRCA1) in 1% (V/V) human serum samples. The combination of a conducting polymer PEDOT with an antifouling and biocompatible polypeptide demonstrates a new method for preparing electrochemical sensors, that are capable of detecting targets in complex biological samples without strong nonspecific protein adsorption. (C) 2020 Elsevier B.V. All rights reserved.
COA
Publication 
Loading ......
